June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
In Vitro Potency of Tobramycin Against Common Bacterial Pathogens Implicated in Blepharitis
Author Affiliations & Notes
  • James E Deom
    Hazleton Eye Specialists, Hazle Township, Pennsylvania, United States
  • Megan E Cavet
    Medical Affairs, Bausch + Lomb, Rochester, New York, United States
  • Christine M Sanfilippo
    Medical Affairs, Bausch + Lomb, Rochester, New York, United States
  • Heleen H DeCory
    Medical Affairs, Bausch + Lomb, Rochester, New York, United States
  • Footnotes
    Commercial Relationships   James Deom, Bausch Health US, LLC (C); Megan Cavet, Bausch Health US, LLC (E); Christine Sanfilippo, Bausch Health US, LLC (E); Heleen DeCory, Bausch Health US, LLC (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 414. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      James E Deom, Megan E Cavet, Christine M Sanfilippo, Heleen H DeCory; In Vitro Potency of Tobramycin Against Common Bacterial Pathogens Implicated in Blepharitis. Invest. Ophthalmol. Vis. Sci. 2021;62(8):414.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although the etiology of blepharitis is not fully understood, bacteria are commonly implicated. Combination topical antibiotic/corticosteroid medications are often used as a short-term therapy with or without lid hygiene. We evaluated the in vitro potency of the anti-infective in the combination product loteprednol etabonate 0.5%/tobramycin 0.3% (Zylet®, Bausch + Lomb) against common bacterial pathogens implicated in blepharitis.

Methods : The antibacterial activity of tobramycin was tested against 487 isolates from 14 genera (67 species) known to be associated with blepharitis. Minimum inhibitory concentrations (MICs) were determined by broth microdilution or agar dilution as appropriate per CLSI M07 and M11 guidelines. ATCC strains were included for quality control (QC) testing.

Results : The MIC range, MIC50 (MICs for 50% of isolates) and MIC90 (MIC for 90% of isolates) for tobramycin are shown in the table. The MIC50/MIC90 against the subset of methicillin-sensitive and methicillin-resistant staphylococci were, respectively, 0.25/0.5 and 0.5/>64 for Staphylococcus aureus and 0.12/0.25 and 0.12/16 for Staphylococcus epidermidis. All QC data were within CLSI approved ranges.

Conclusions : Tobramycin demonstrated low MICs against most bacterial species associated with blepharitis, including staphylococci and most methicillin-resistant strains thereof. Together with previous published clinical studies, these data support the use of combination loteprednol etabonate 0.5%/tobramycin 0.3% in the treatment of blepharitis, including in staphylococcal blepharitis.

This is a 2021 ARVO Annual Meeting abstract.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×